Literature DB >> 6619826

Differential epileptogenic potentials of selective mu and delta opiate receptor agonists.

J Haffmans, M R Dzoljic.   

Abstract

By using electroencephalographic (EEG) and electromyographic recordings in anaesthetized and free-moving rats, two opioid peptides, known as selective agonists for mu and delta opiate receptors, respectively, were examined for their epileptogenic properties. The delta receptor peptide (DSTLE, 4.6-18.6 nmol, intraventricularly, ivt), a putative delta opiate agonist, produced a dose-related increase of myoclonic contractions (MC) with epileptic discharges in anaesthetized rats and severe wet dog shakes, with occasionally falling down, in free-moving animals. Morphiceptin, a specific mu opiate agonist, used in equimolar doses and under the same experimental conditions, had a significantly less pronounced effect on the number of MC and epileptiform EEG phenomena. Similarly, DSTLE (18.6 nmol) injected in the CA2 area of the hippocampus, a region with a nearly equal distribution of mu and delta opiate receptors, induced epileptic discharges in anaesthetized and free-moving rats, while an equimolar dose of morphiceptin had no significant effect. It is suggested that the epileptiform activity of opioid peptides is mainly due to an activation of delta opiate receptors in the central nervous system.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6619826     DOI: 10.1007/bf01250043

Source DB:  PubMed          Journal:  J Neural Transm            Impact factor:   3.575


  26 in total

1.  Electrophysiological indices of opiate action in awake and anesthetized rats.

Authors:  G Urca; J C Liebeskind
Journal:  Brain Res       Date:  1979-01-26       Impact factor: 3.252

2.  Epileptic properties of leucine- and methionine-enkephalin: comparison with morphine and reversibility by naloxone.

Authors:  H Frenk; G Urca; J C Liebeskind
Journal:  Brain Res       Date:  1978-05-26       Impact factor: 3.252

3.  A model for the quantitative study of central dopaminergic and serotoninergic activity.

Authors:  D Bieger; L Larochelle; O Hornykiewicz
Journal:  Eur J Pharmacol       Date:  1972-04       Impact factor: 4.432

4.  The actions of naloxazone on the binding and analgesic properties of morphiceptin (NH2Tyr-Pro-Phe-Pro-CONH2), a selective mu-receptor ligand.

Authors:  A Z Zhang; J K Chang; G W Pasternak
Journal:  Life Sci       Date:  1981-06-22       Impact factor: 5.037

5.  The role of the nucleus accumbens and nigrostriatum in enkephalin-induced myoclonus.

Authors:  M R Dzoljic; A L van der Poel-Heisterkamp
Journal:  Pharmacol Biochem Behav       Date:  1980-07       Impact factor: 3.533

6.  Effect of opiate receptor agonists on striatally-mediated head turning: an in vivo model of opiate delta receptor activation?

Authors:  H Wheeler
Journal:  Neuropharmacology       Date:  1982-09       Impact factor: 5.250

7.  Endogenous opioid peptides: multiple agonists and receptors.

Authors:  J A Lord; A A Waterfield; J Hughes; H W Kosterlitz
Journal:  Nature       Date:  1977-06-09       Impact factor: 49.962

8.  Morphiceptin ( beta-casomorphin (1-4) amide): a peptide opioid antagonist in the field stimulated rat vas deferens.

Authors:  A R Day; R J Freer; C S Liao
Journal:  Res Commun Chem Pathol Pharmacol       Date:  1981-12

9.  An iontophoretic survey of opioid peptide actions in the rat limbic system: in search of opiate epileptogenic mechanisms.

Authors:  E D French; G R Siggins
Journal:  Regul Pept       Date:  1980-10

10.  Involvement of mu-receptors in the opioid-induced generation of bursting discharges in hippocampal pyramidal cells.

Authors:  B H Gähwiler; R Maurer
Journal:  Regul Pept       Date:  1981-05
View more
  8 in total

1.  Peptidic delta opioid receptor agonists produce antidepressant-like effects in the forced swim test and regulate BDNF mRNA expression in rats.

Authors:  Mary M Torregrossa; Emily M Jutkiewicz; Henry I Mosberg; Gianfranco Balboni; Stanley J Watson; James H Woods
Journal:  Brain Res       Date:  2005-12-20       Impact factor: 3.252

2.  Delta-opioid receptor activation prolongs respiratory motor output during oxygen-glucose deprivation in neonatal rat spinal cord in vitro.

Authors:  S M F Turner; S M Johnson
Journal:  Neuroscience       Date:  2011-05-06       Impact factor: 3.590

3.  Differential behavioral tolerance to the delta-opioid agonist SNC80 ([(+)-4-[(alphaR)-alpha-[(2S,5R)-2,5-dimethyl-4-(2-propenyl)-1-piperazinyl]-(3-methoxyphenyl)methyl]-N,N-diethylbenzamide) in Sprague-Dawley rats.

Authors:  Emily M Jutkiewicz; Sarah T Kaminsky; Kenner C Rice; John R Traynor; James H Woods
Journal:  J Pharmacol Exp Ther       Date:  2005-07-13       Impact factor: 4.030

4.  NOP receptor agonist attenuates nitroglycerin-induced migraine-like symptoms in mice.

Authors:  Katarzyna M Targowska-Duda; Akihiko Ozawa; Zachariah Bertels; Andrea Cippitelli; Jason L Marcus; Hanna K Mielke-Maday; Gilles Zribi; Amanda N Rainey; Brigitte L Kieffer; Amynah A Pradhan; Lawrence Toll
Journal:  Neuropharmacology       Date:  2020-03-06       Impact factor: 5.250

5.  Behavioral and neurobiological effects of the enkephalinase inhibitor RB101 relative to its antidepressant effects.

Authors:  Emily M Jutkiewicz; Mary M Torregrossa; Katarzyna Sobczyk-Kojiro; Henry I Mosberg; John E Folk; Kenner C Rice; Stanley J Watson; James H Woods
Journal:  Eur J Pharmacol       Date:  2006-01-25       Impact factor: 4.432

6.  Comparison of peptidic and nonpeptidic delta-opioid agonists on guanosine 5'-O-(3-[35S]thio)triphosphate ([35S]GTPgammaS) binding in brain slices from Sprague-Dawley rats.

Authors:  Emily M Jutkiewicz; Nicholas P Walker; John E Folk; Kenner C Rice; Philip S Portoghese; James H Woods; John R Traynor
Journal:  J Pharmacol Exp Ther       Date:  2004-12-01       Impact factor: 4.030

7.  Enkephalinase inhibition antagonizes the increased susceptibility to seizure induced by REM sleep deprivation.

Authors:  O E Ukponmwan; M R Dzoljic
Journal:  Psychopharmacology (Berl)       Date:  1984       Impact factor: 4.530

8.  Exploration of beta-arrestin isoform signaling pathways in delta opioid receptor agonist-induced convulsions.

Authors:  Arryn T Blaine; Yiming Miao; Jinling Yuan; Sophia Palant; Rebecca J Liu; Zhong-Yin Zhang; Richard M van Rijn
Journal:  Front Pharmacol       Date:  2022-08-11       Impact factor: 5.988

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.